T1	tradename 114 121	ZEVALIN
T3	tradename 185 193	ZEVALIN.
T5	tradename 196 203	ZEVALIN
T7	nanoparticle 205 226	ibritumomab tiuxetan)
T9	routeofadministration 242 253	intravenous
T11	fdaapprovaldate 281 285	2002
T13	adversereaction 477 495	Infusion Reactions
T15	co-administereddrug 538 547	rituximab
T17	adversereaction 586 596	Cytopenias
T19	adversereaction 628 672	Severe Cutaneous and Mucocutaneous Reactions
T21	tradename 700 707	Zevalin
T23	activeingredient 776 780	Y-90
T25	tradename 781 789	Zevalin.
T27	tradename 1039 1046	Zevalin
T29	chemoclass 1052 1065	CD20-directed
T31	tradename 1120 1127	Zevalin
T33	indication 1242 1262	B-cell non-Hodgkin's
T35	indication 1264 1278	lymphoma (NHL)
T37	indication 1319 1322	NHL
T39	co-administereddrug 1491 1500	rituximab
T41	dose 1501 1510	250 mg/m2
T43	routeofadministration 1511 1523	intravenous.
T45	co-administereddrug 1559 1568	rituximab
T47	dose 1569 1578	250 mg/m2
T49	routeofadministration 1579 1590	intravenous
T51	co-administereddrug 1655 1664	rituximab
T53	dose 1686 1696	0.4 mCi/kg
T55	dose 1698 1714	14.8 MBq per kg)
T57	activeingredient 1715 1719	Y-90
T59	tradename 1720 1727	Zevalin
T61	routeofadministration 1728 1740	intravenous.
T63	co-administereddrug 1838 1847	rituximab
T65	dose 1869 1879	0.3 mCi/kg
T67	dose 1881 1897	11.1 MBq per kg)
T69	activeingredient 1898 1902	Y-90
T71	tradename 1903 1910	Zevalin
T73	routeofadministration 1911 1923	intravenous.
T75	adversereaction 2196 2223	Serious Infusion Reactions:
T77	co-administereddrug 2248 2257	rituximab
T79	activeingredient 2266 2268	90
T81	tradename 2269 2277	Zevalin.
T83	adversereaction 2289 2321	Prolonged and Severe Cytopenias:
T85	tradename 2340 2347	Zevalin
T87	adversereaction 2454 2499	Severe Cutaneous and Mucocutaneous Reactions:
T89	co-administereddrug 2512 2521	rituximab
T91	tradename 2526 2533	Zevalin
T93	adversereaction 2564 2608	severe cutaneous or mucocutaneous reactions.
T95	adversereaction 2669 2677	Leukemia
T97	adversereaction 2682 2706	Myelodysplastic Syndrome
T99	tradename 2932 2940	Zevalin.
T101	adversereaction 2947 2969	Embryo-fetal Toxicity:
T103	adversereaction 3170 3180	cytopenias
T105	adversereaction 3182 3189	fatigue
T107	adversereaction 3191 3206	nasopharyngitis
T109	adversereaction 3208 3214	nausea
T111	adversereaction 3216 3230	abdominal pain
T113	adversereaction 3232 3240	asthenia
T115	adversereaction 3242 3247	cough
T117	adversereaction 3249 3257	diarrhea
T119	adversereaction 3263 3271	pyrexia.
T121	company 3324 3348	Spectrum Pharmaceuticals
T123	company 3350 3354	Inc.
T125	tradename 4048 4055	Zevalin
T127	activeingredient 4150 4154	Y-90
T129	tradename 4155 4162	Zevalin
T131	adversereaction 4333 4359	Serious Infusion Reactions
T133	adversereaction 4365 4396	Prolonged and Severe Cytopenias
T135	adversereaction 4402 4446	Severe Cutaneous and Mucocutaneous Reactions
T137	adversereaction 4500 4524	Myelodysplastic Syndrome
T139	adversereaction 4526 4534	Leukemia
T141	adversereaction 4639 4660	Embryo-Fetal Toxicity
T143	adversereaction 5518 5544	SERIOUS INFUSION REACTIONS
T145	adversereaction 5546 5577	PROLONGED AND SEVERE CYTOPENIAS
T147	adversereaction 5583 5627	SEVERE CUTANEOUS AND MUCOCUTANEOUS REACTIONS
T149	adversereaction 5630 5657	Serious Infusion Reactions:
T151	co-administereddrug 5699 5708	rituximab
T153	tradename 5749 5756	Zevalin
T155	adversereaction 5817 5824	hypoxia
T157	adversereaction 5826 5847	pulmonary infiltrates
T159	adversereaction 5849 5884	acute respiratory distress syndrome
T161	adversereaction 5886 5907	myocardial infarction
T163	adversereaction 5909 5933	ventricular fibrillation
T165	adversereaction 5938 5956	cardiogenic shock.
T167	co-administereddrug 6004 6013	rituximab
T169	co-administereddrug 6103 6112	rituximab
T171	activeingredient 6117 6121	Y-90
T173	tradename 6122 6129	Zevalin
T175	adversereaction 6164 6190	severe infusion reactions.
T177	adversereaction 6192 6224	Prolonged and Severe Cytopenias:
T179	activeingredient 6226 6230	Y-90
T181	tradename 6231 6238	Zevalin
T183	adversereaction 6265 6296	severe and prolonged cytopenias
T185	activeingredient 6335 6339	Y-90
T187	tradename 6340 6347	Zevalin
T189	adversereaction 6511 6556	Severe Cutaneous and Mucocutaneous Reactions:
T191	adversereaction 6559 6603	Severe cutaneous and mucocutaneous reactions
T193	tradename 6636 6643	Zevalin
T195	co-administereddrug 6679 6688	rituximab
T197	activeingredient 6693 6697	Y-90
T199	tradename 6698 6705	Zevalin
T201	activeingredient 6872 6876	Y-90
T203	tradename 6877 6884	Zevalin
T205	dose 6903 6911	32.0 mCi
T207	dose 6913 6922	1184 MBq)
T209	indication 6993 7015	Relapsed or Refractory
T211	indication 7017 7044	Low-grade or Follicular NHL
T213	tradename 7047 7054	Zevalin
T215	indication 7089 7111	relapsed or refractory
T217	indication 7113 7173	low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL).
T219	indication 7179 7214	Previously Untreated Follicular NHL
T221	tradename 7216 7223	Zevalin
T223	indication 7258 7293	previously untreated follicular NHL
T225	tradename 7452 7459	Zevalin
T227	tradename 7523 7530	Zevalin
T229	co-administereddrug 7718 7726	Rituxan/
T231	tradename 7726 7733	Zevalin
T233	tradename 7852 7859	Zevalin
T235	co-administereddrug 7931 7944	acetaminophen
T237	routeofadministration 7952 7958	orally
T239	co-administereddrug 7963 7978	diphenhydramine
T241	routeofadministration 7985 7991	orally
T243	co-administereddrug 8001 8010	rituximab
T245	co-administereddrug 8033 8042	rituximab
T247	dose 8043 8052	250 mg/m2
T249	routeofadministration 8053 8066	intravenously
T251	co-administereddrug 8256 8265	rituximab
T253	co-administereddrug 8306 8315	rituximab
T255	adversereaction 8329 8355	serious infusion reactions
T257	tradename 8376 8383	Zevalin
T259	co-administereddrug 8495 8504	rituximab
T261	adversereaction 8523 8549	severe infusion reactions.
T263	co-administereddrug 8661 8674	acetaminophen
T265	routeofadministration 8682 8688	orally
T267	co-administereddrug 8693 8708	diphenhydramine
T269	routeofadministration 8715 8721	orally
T271	co-administereddrug 8731 8740	rituximab
T273	co-administereddrug 8763 8772	rituximab
T275	dose 8773 8782	250 mg/m2
T277	routeofadministration 8783 8796	intravenously
T279	adversereaction 8940 8958	infusion reactions
T281	co-administereddrug 8975 8984	rituximab
T283	co-administereddrug 9028 9037	rituximab
T285	activeingredient 9180 9184	Y-90
T287	tradename 9185 9192	Zevalin
T289	co-administereddrug 9282 9291	rituximab
T291	activeingredient 9514 9518	Y-90
T293	tradename 9519 9526	Zevalin
T295	routeofadministration 9549 9560	intravenous
T297	activeingredient 9584 9588	Y-90
T299	dose 9589 9603	0.4 mCi per kg
T301	dose 9605 9621	14.8 MBq per kg)
T303	activeingredient 9733 9737	Y-90
T305	tradename 9738 9745	Zevalin
T307	routeofadministration 9768 9779	intravenous
T309	activeingredient 9803 9807	Y-90
T311	dose 9808 9822	0.3 mCi per kg
T313	dose 9824 9840	11.1 MBq per kg)
T315	dose 9890 9896	32 mCi
T317	dose 9898 9907	1184 MBq)
T319	activeingredient 9908 9912	Y-90
T321	tradename 9913 9920	Zevalin
T323	activeingredient 10047 10051	Y-90
T325	tradename 10052 10060	Zevalin.
T327	activeingredient 10252 10256	Y-90
T329	tradename 10257 10264	Zevalin
T331	activeingredient 10325 10342	Yttrium-90 (Y-90)
T333	tradename 10343 10351	Zevalin.
T335	tradename 10423 10430	Zevalin
T337	activeingredient 10519 10529	Yttrium-90
T339	inactiveingredient 10725 10740	Sodium Chloride
T341	activeingredient 10992 10996	Y-90
T343	activeingredient 11046 11050	Y-90
T345	tradename 11051 11058	Zevalin
T347	tradename 11064 11071	Zevalin
T349	inactiveingredient 11084 11098	sodium acetate
T351	activeingredient 11305 11309	Y-90
T353	activeingredient 11383 11387	Y-90
T355	inactiveingredient 11428 11442	Sodium Acetate
T357	activeingredient 11486 11490	Y-90
T359	inactiveingredient 11702 11716	Sodium Acetate
T361	activeingredient 11853 11857	Y-90
T363	tradename 12002 12009	Zevalin
T365	nanoparticle 12011 12032	ibritumomab tiuxetan)
T367	activeingredient 12665 12670	Y-90.
T369	activeingredient 12933 12937	Y-90
T371	tradename 12938 12945	Zevalin
T373	activeingredient 13117 13122	Y-90.
T375	activeingredient 13187 13191	Y-90
T377	tradename 13192 13199	Zevalin
T379	dose 13220 13226	32 mCi
T381	dose 13228 13237	1184 MBq)
T383	activeingredient 13518 13528	Yttrium-90
T385	tradename 13529 13536	Zevalin
T387	activeingredient 13759 13764	Y-90.
T389	activeingredient 13867 13871	Y-90
T391	tradename 13872 13880	Zevalin:
T393	activeingredient 13907 13911	Y-90
T395	tradename 13912 13919	Zevalin
T397	inactiveingredient 14118 14123	NaCl)
T399	activeingredient 14546 14550	Y-90
T401	tradename 14551 14558	Zevalin
T403	tradename 14620 14627	Zevalin
T405	activeingredient 14673 14677	Y-90
T407	tradename 14678 14685	Zevalin
T409	tradename 14855 14862	Zevalin
T411	activeingredient 15225 15229	Y-90
T413	tradename 15230 15237	Zevalin
T415	activeingredient 15247 15251	Y-90
T417	tradename 15252 15259	Zevalin
T419	nanoparticle 16660 16680	ibritumomab tiuxetan
T421	adversereaction 16775 16801	Serious Infusion Reactions
T423	co-administereddrug 16840 16860	rituximab. Rituximab
T425	tradename 16893 16900	Zevalin
T427	adversereaction 16957 16976	infusion reactions.
T429	co-administereddrug 17027 17036	rituximab
T431	adversereaction 17111 17136	severe infusion reactions
T433	adversereaction 17149 17158	urticaria
T435	adversereaction 17160 17171	hypotension
T437	adversereaction 17173 17183	angioedema
T439	adversereaction 17185 17192	hypoxia
T441	adversereaction 17194 17206	bronchospasm
T443	adversereaction 17208 17229	pulmonary infiltrates
T445	adversereaction 17231 17266	acute respiratory distress syndrome
T447	adversereaction 17268 17289	myocardial infarction
T449	adversereaction 17291 17315	ventricular fibrillation
T451	adversereaction 17321 17339	cardiogenic shock.
T453	co-administereddrug 17375 17384	rituximab
T455	adversereaction 17403 17429	severe infusion reactions.
T457	co-administereddrug 17455 17464	rituximab
T459	activeingredient 17469 17473	Y-90
T461	tradename 17474 17481	Zevalin
T463	adversereaction 17501 17527	severe infusion reactions.
T465	co-administereddrug 17546 17554	Rituxan/
T467	tradename 17554 17561	Zevalin
T469	adversereaction 17701 17732	Prolonged and Severe Cytopenias
T471	adversereaction 17734 17744	Cytopenias
T473	adversereaction 17808 17818	hemorrhage
T475	adversereaction 17823 17839	severe infection
T477	tradename 17893 17900	Zevalin
T479	adversereaction 17991 18007	thrombocytopenia
T481	adversereaction 18012 18023	neutropenia
T483	adversereaction 18067 18083	thrombocytopenia
T485	adversereaction 18179 18189	cytopenias
T487	tradename 18327 18334	Zevalin
T489	tradename 18484 18491	Zevalin
T491	adversereaction 18620 18630	cytopenias
T493	adversereaction 18662 18681	febrile neutropenia
T495	adversereaction 18683 18694	hemorrhage)
T497	tradename 18731 18738	Zevalin
T499	tradename 18848 18855	Zevalin
T501	adversereaction 18883 18927	Severe Cutaneous and Mucocutaneous Reactions
T503	adversereaction 18929 18948	Erythema multiforme
T505	adversereaction 18950 18974	Stevens-Johnson syndrome
T507	adversereaction 18976 19002	toxic epidermal necrolysis
T509	adversereaction 19004 19022	bullous dermatitis
T511	adversereaction 19028 19050	exfoliative dermatitis
T513	tradename 19225 19232	Zevalin
T515	tradename 19272 19279	Zevalin
T517	adversereaction 19327 19369	severe cutaneous or mucocutaneous reaction
T519	adversereaction 19718 19742	Myelodysplastic Syndrome
T521	adversereaction 19744 19752	Leukemia
T523	activeingredient 19836 19840	Y-90
T525	tradename 19854 19861	Zevalin
T527	adversereaction 19901 19931	Myelodysplastic syndrome (MDS)
T529	adversereaction 19939 19971	acute myelogenous leukemia (AML)
T531	indication 20020 20046	relapsed or refractory NHL
T533	adversereaction 20269 20272	MDS
T535	adversereaction 20276 20279	AML
T537	tradename 20323 20330	Zevalin
T539	activeingredient 20469 20473	Y-90
T541	tradename 20474 20481	Zevalin
T543	tradename 20544 20551	Zevalin
T545	adversereaction 20699 20706	MDS/AML
T547	tradename 20723 20730	Zevalin
T549	tradename 20904 20911	Zevalin
T551	adversereaction 20968 20974	Deaths
T553	adversereaction 20982 20989	MDS/AML
T555	tradename 21027 21034	Zevalin
T557	tradename 21166 21173	Zevalin
T559	tradename 21427 21434	Zevalin
T561	tradename 21556 21564	Zevalin.
T563	tradename 21639 21646	Zevalin
T565	tradename 21751 21758	Zevalin
T567	activeingredient 21764 21768	Y-90
T569	adversereaction 21939 21960	Embryo-Fetal Toxicity
T571	activeingredient 21990 21994	Y-90
T573	tradename 21995 22002	Zevalin
T575	tradename 22072 22079	Zevalin
T577	adversereaction 22471 22497	Serious Infusion Reactions
T579	adversereaction 22555 22586	Prolonged and Severe Cytopenias
T581	adversereaction 22644 22688	Severe Cutaneous and Mucocutaneous Reactions
T583	adversereaction 22746 22754	Leukemia
T585	adversereaction 22759 22783	Myelodysplastic Syndrome
T587	tradename 22860 22867	Zevalin
T589	adversereaction 22872 22882	cytopenias
T591	adversereaction 22884 22891	fatigue
T593	adversereaction 22893 22908	nasopharyngitis
T595	adversereaction 22910 22916	nausea
T597	adversereaction 22918 22932	abdominal pain
T599	adversereaction 22934 22942	asthenia
T601	adversereaction 22944 22949	cough
T603	adversereaction 22951 22959	diarrhea
T605	adversereaction 22965 22973	pyrexia.
T607	tradename 23013 23020	Zevalin
T609	adversereaction 23025 23056	prolonged and severe cytopenias
T611	adversereaction 23058 23074	thrombocytopenia
T613	adversereaction 23076 23082	anemia
T615	adversereaction 23084 23095	lymphopenia
T617	adversereaction 23097 23109	neutropenia)
T619	tradename 23151 23158	Zevalin
T621	co-administereddrug 23199 23208	rituximab
T623	co-administereddrug 23242 23252	rituximab.
T625	tradename 23598 23605	Zevalin
T627	indication 23627 23649	relapsed or refractory
T629	indication 23651 23660	low-grade
T631	indication 23662 23691	follicular or transformed NHL
T633	indication 23765 23800	previously untreated follicular NHL
T635	tradename 23865 23872	Zevalin
T637	tradename 23932 23939	Zevalin
T639	indication 23961 23987	relapsed or refractory NHL
T641	dose 24045 24055	0.4 mCi/kg
T643	dose 24057 24069	14.8 MBq/kg)
T645	activeingredient 24073 24077	Y-90
T647	tradename 24078 24085	Zevalin
T649	indication 24125 24151	relapsed or refractory NHL
T651	dose 24224 24234	0.3 mCi/kg
T653	dose 24236 24248	11.1 MBq/kg)
T655	activeingredient 24253 24257	Y-90
T657	tradename 24258 24265	Zevalin
T659	indication 24310 24334	previously untreated NHL
T661	dose 24382 24392	0.4 mCi/kg
T663	dose 24394 24406	14.8 MBq/kg)
T665	activeingredient 24410 24414	Y-90
T667	tradename 24415 24422	Zevalin
T669	tradename 24465 24473	Zevalin.
T671	tradename 24579 24586	Zevalin
T673	indication 24802 24837	Previously Untreated Follicular NHL
T675	tradename 24855 24862	Zevalin
T677	tradename 24884 24891	Zevalin
T679	adversereaction 25004 25018	Abdominal pain
T681	adversereaction 25034 25042	Diarrhea
T683	adversereaction 25053 25059	Nausea
T685	adversereaction 25088 25096	Asthenia
T687	adversereaction 25111 25118	Fatigue
T689	adversereaction 25129 25151	Influenza-like illness
T691	adversereaction 25161 25168	Pyrexia
T693	adversereaction 25197 25204	Myalgia
T695	adversereaction 25225 25233	Anorexia
T697	adversereaction 25277 25282	Cough
T699	adversereaction 25297 25319	Pharyngolaryngeal pain
T701	adversereaction 25329 25338	Epistaxis
T703	adversereaction 25352 25376	Nervous System Dizziness
T705	adversereaction 25386 25407	Vascular Hypertension
T707	adversereaction 25450 25462	Night sweats
T709	adversereaction 25472 25481	Petechiae
T711	adversereaction 25491 25499	Pruritus
T713	adversereaction 25508 25509	R
T715	adversereaction 25510 25513	ash
T717	adversereaction 25559 25569	Bronchitis
T719	adversereaction 25579 25594	Nasopharyngitis
T721	adversereaction 25606 25614	Rhinitis
T723	adversereaction 25624 25633	Sinusitis
T725	adversereaction 25650 25673	Urinary tract infection
T727	adversereaction 25716 25732	Thrombocytopenia
T729	adversereaction 25744 25755	Neutropenia
T731	adversereaction 25767 25773	Anemia
T733	adversereaction 25784 25794	Leukopenia
T735	adversereaction 25805 25806	L
T737	adversereaction 25807 25817	ymphopenia
T739	tradename 25944 25959	Zevalin-treated
T741	indication 25974 25996	relapsed or refractory
T743	indication 25998 26007	low-grade
T745	indication 26009 26046	follicular or transformed B-cell NHL.
T747	tradename 26099 26114	Zevalin-treated
T749	indication 26213 26245	Relapsed or Refractory Low-grade
T751	indication 26247 26284	Follicular or Transformed B-cell NHLa
T753	adversereaction 26322 26338	Thrombocytopenia
T755	adversereaction 26345 26356	Neutropenia
T757	adversereaction 26363 26369	Anemia
T759	adversereaction 26376 26386	Ecchymosis
T761	co-administereddrug 26450 26459	rituximab
T763	tradename 26476 26483	Zevalin
T765	adversereaction 26505 26536	Prolonged and Severe Cytopenias
T767	tradename 26674 26681	Zevalin
T769	indication 26765 26787	previously treated NHL
T771	activeingredient 26861 26865	Y-90
T773	tradename 26866 26873	Zevalin
T775	tradename 26958 26965	Zevalin
T777	activeingredient 27093 27097	Y-90
T779	tradename 27098 27105	Zevalin
T781	dose 27112 27122	0.4 mCi/kg
T783	dose 27124 27147	14.8 MBq/kg) 0.3 mCi/kg
T785	dose 27150 27173	11.1 MBq/kg) 0.4 mCi/kg
T787	dose 27176 27188	14.8 MBq/kg)
T789	adversereaction 28039 28049	Cytopenias
T791	tradename 28126 28133	Zevalin
T793	adversereaction 28704 28713	cytopenia
T795	indication 28747 28770	relapsed/refractory NHL
T797	activeingredient 28925 28930	Y-90-
T799	tradename 28930 28937	Zevalin
T801	indication 29057 29080	relapsed/refractory NHL
T803	tradename 29263 29270	Zevalin
T805	tradename 29465 29480	Zevalin-treated
T807	indication 29556 29582	relapsed or refractory NHL
T809	tradename 29612 29619	Zevalin
T811	indication 29669 29695	relapsed or refractory NHL
T813	tradename 29796 29803	Zevalin
T815	adversereaction 29861 29884	urinary tract infection
T817	adversereaction 29886 29905	febrile neutropenia
T819	adversereaction 29907 29913	sepsis
T821	adversereaction 29915 29924	pneumonia
T823	adversereaction 29926 29936	cellulitis
T825	adversereaction 29938 29945	colitis
T827	adversereaction 29947 29955	diarrhea
T829	adversereaction 29957 29970	osteomyelitis
T831	adversereaction 29976 30010	upper respiratory tract infection)
T833	adversereaction 30063 30069	sepsis
T835	adversereaction 30071 30078	empyema
T837	adversereaction 30080 30089	pneumonia
T839	adversereaction 30091 30110	febrile neutropenia
T841	adversereaction 30112 30117	fever
T843	adversereaction 30123 30160	biliary stent-associated cholangitis)
T845	tradename 30195 30202	Zevalin
T847	adversereaction 30268 30291	urinary tract infection
T849	adversereaction 30293 30321	bacterial or viral pneumonia
T851	adversereaction 30323 30342	febrile neutropenia
T853	adversereaction 30344 30364	perihilar infiltrate
T855	adversereaction 30366 30378	pericarditis
T857	routeofadministration 30384 30395	intravenous
T859	adversereaction 30412 30428	viral hepatitis)
T861	adversereaction 30471 30490	bacterial pneumonia
T863	adversereaction 30492 30511	respiratory disease
T865	adversereaction 30517 30524	sepsis)
T867	tradename 30629 30636	Zevalin
T869	adversereaction 30689 30707	neutropenic sepsis
T871	adversereaction 30714 30724	bronchitis
T873	adversereaction 30726 30741	catheter sepsis
T875	adversereaction 30743 30757	diverticulitis
T877	adversereaction 30759 30772	herpes zoster
T879	adversereaction 30774 30783	influenza
T881	adversereaction 30785 30818	lower respiratory tract infection
T883	adversereaction 30820 30829	sinusitis
T885	adversereaction 30835 30869	upper respiratory tract infection.
T887	adversereaction 30871 30879	Leukemia
T889	adversereaction 30884 30908	Myelodysplastic Syndrome
T891	indication 30933 30956	relapsed/refractory NHL
T893	adversereaction 30987 30994	MDS/AML
T895	adversereaction 31060 31067	MDS/AML
T897	adversereaction 31214 31221	MDS/AML
T899	adversereaction 31289 31311	MDS/secondary leukemia
T901	adversereaction 31399 31406	MDS/AML
T903	adversereaction 31550 31557	MDS/AML
T905	adversereaction 31687 31694	MDS/AML
T907	activeingredient 31799 31804	Y-90-
T909	tradename 31804 31811	Zevalin
T911	adversereaction 31870 31877	MDS/AML
T913	tradename 31919 31926	Zevalin
T915	tradename 32098 32105	Zevalin
T917	tradename 32576 32583	Zevalin
T919	adversereaction 32646 32665	erythema multiforme
T921	adversereaction 32667 32691	Stevens-Johnson syndrome
T923	adversereaction 32693 32719	toxic epidermal necrolysis
T925	adversereaction 32721 32739	bullous dermatitis
T927	adversereaction 32745 32767	exfoliative dermatitis
T929	adversereaction 32826 32848	Infusion site erythema
T931	adversereaction 32853 32863	ulceration
T933	tradename 33013 33020	Zevalin
T935	tradename 33580 33587	Zevalin
T937	tradename 33958 33965	Zevalin
T939	tradename 34354 34361	Zevalin
T941	tradename 34635 34643	Zevalin.
T943	activeingredient 34947 34951	Y-90
T945	tradename 34953 34960	Zevalin
T947	tradename 35187 35194	Zevalin
T949	tradename 35373 35380	Zevalin
T951	tradename 35499 35506	Zevalin
T953	activeingredient 35612 35616	Y-90
T955	tradename 35617 35624	Zevalin
T957	tradename 35697 35704	Zevalin
T959	tradename 35841 35848	Zevalin
T961	indication 35940 35963	relapsed/refractory NHL
T963	tradename 35981 35988	Zevalin
T965	tradename 36168 36175	Zevalin
T967	tradename 36233 36241	Zevalin.
T969	adversereaction 36662 36672	cytopenias
T971	dose 36782 36788	32 mCi
T973	dose 36790 36799	1184 MBq)
T975	tradename 36819 36826	Zevalin
T977	nanoparticle 36828 36849	ibritumomab tiuxetan)
T979	corecomposition 36952 36963	ibritumomab
T981	activeingredient 36988 37116	tiuxetan [N-[2-bis(carboxymethyl)amino](p-isothiocyanatophenyl)-propyl]-[N-[2-bis(carboxymethyl)amino]-2-(methyl)-ethyl]glycine.
T983	activeingredient 37213 37224	Yttrium-90.
T985	nanoparticle 37263 37283	ibritumomab tiuxetan
T987	molecularweight 37287 37294	148 kD.
T989	tradename 37320 37327	Zevalin
T991	corecomposition 37331 37342	ibritumomab
T993	corecomposition 37346 37383	murine IgG1 kappa monoclonal antibody
T995	nanoparticle 37420 37440	Ibritumomab tiuxetan
T997	nanoparticle 37594 37614	ibritumomab tiuxetan
T999	inactiveingredient 37631 37647	Sodium Chloride.
T1001	activeingredient 37691 37706	Y-90 Yttrium-90
T1003	activeingredient 37964 37968	Y-90
T1005	activeingredient 38018 38022	Y-90
T1007	activeingredient 38187 38191	Y-90
T1009	activeingredient 38248 38252	Y-90
T1011	activeingredient 38452 38456	Y-90
T1013	nanoparticle 38818 38838	Ibritumomab tiuxetan
T1015	nanoparticle 38972 38992	ibritumomab tiuxetan
T1017	indication 39140 39177	B-cell non-Hodgkin's lymphomas (NHL).
T1019	surfacecoating 39292 39300	tiuxetan
T1021	activeingredient 39322 39326	Y-90
T1023	corecomposition 39352 39364	ibritumomab.
T1025	activeingredient 39390 39394	Y-90
T1027	nanoparticle 39491 39511	Ibritumomab tiuxetan
T1029	tradename 39824 39831	Zevalin
T1031	tradename 40539 40546	Zevalin
T1033	dose 40548 40553	5 mCi
T1035	dose 40555 40563	185 MBq]
T1037	dose 40572 40578	1.6 mg
T1039	nanoparticle 40579 40600	ibritumomab tiuxetan)
T1041	tradename 40755 40762	Zevalin
T1043	dose 40853 40862	1.0 mg/kg
T1045	dose 40866 40876	2.5 mg/kg)
T1047	tradename 40885 40892	Zevalin
T1049	tradename 40989 40996	Zevalin
T1051	tradename 41108 41115	Zevalin
T1053	activeingredient 41170 41174	Y-90
T1055	eliminationhalflife 41197 41205	30 hours
T1057	auc 41299 41308	39 hours.
T1059	tradename 41672 41679	Zevalin
T1061	tradename 41741 41748	Zevalin
T1063	tradename 41960 41967	Zevalin
T1065	tradename 42149 42156	Zevalin
T1067	tradename 42646 42653	Zevalin
T1069	tradename 42711 42718	Zevalin
T1071	co-administereddrug 42759 42768	rituximab
T1073	indication 43143 43146	NHL
T1075	co-administereddrug 43262 43271	rituximab
T1077	indication 43860 43935	relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL)
T1079	co-administereddrug 43967 43977	rituximab.
T1081	indication 44089 44092	NHL
T1083	tradename 44204 44211	Zevalin
T1085	co-administereddrug 44258 44267	rituximab
T1087	routeofadministration 44280 44282	IV
T1089	dose 44295 44308	375 mg per m2
T1091	frequency 44309 44315	weekly
T1093	tradename 44465 44472	Zevalin
T1095	tradename 44704 44711	Zevalin
T1097	tradename 44740 44747	Zevalin
T1099	indication 45096 45128	relapsed or refractory low-grade
T1101	indication 45130 45144	follicular NHL
T1103	activeingredient 45441 45445	Y-90
T1105	tradename 45446 45453	Zevalin
T1107	dose 45455 45469	0.3 mCi per kg
T1109	dose 45471 45487	11.1 MBq per kg)
T1111	indication 45655 45665	Follicular
T1113	indication 45667 45677	B-Cell NHL
T1115	indication 45806 45820	follicular NHL
T1117	tradename 46208 46215	Zevalin
T1119	activeingredient 46257 46261	Y-90
T1121	tradename 46262 46269	Zevalin
T1123	indication 46545 46567	non-Hodgkin's Lymphoma
T1125	co-administereddrug 47027 47047	rituximab-containing
T1127	tradename 47159 47174	Zevalin-treated
T1129	activeingredient 47740 47744	Y-90
T1131	tradename 47758 47765	Zevalin
T1133	tradename 47977 47984	Zevalin
T1135	nanoparticle 48008 48028	ibritumomab tiuxetan
T1137	inactiveingredient 48042 48057	Sodium Chloride
T1139	inactiveingredient 48107 48121	Sodium Acetate
T1141	inactiveingredient 48146 48171	Sodium Acetate trihydrate
T1143	inactiveingredient 48180 48185	Water
T1145	inactiveingredient 48290 48297	Albumin
T1147	inactiveingredient 48313 48328	Sodium Chloride
T1149	inactiveingredient 48336 48374	Sodium Phosphate Dibasic Dodecahydrate
T1151	inactiveingredient 48381 48394	Pentetic Acid
T1153	inactiveingredient 48401 48430	Potassium Phosphate Monobasic
T1155	inactiveingredient 48440 48458	Potassium Chloride
T1157	inactiveingredient 48468 48473	Water
T1159	activeingredient 48576 48586	Yttrium-90
T1161	activeingredient 48686 48690	Y-90
T1163	tradename 48691 48698	Zevalin
T1165	co-administereddrug 48704 48713	Rituximab
T1167	company 48720 48731	Biogen Idec
T1169	company 48736 48750	Genentech USA)
T1171	adversereaction 48964 48983	infusion reactions.
T1173	adversereaction 49132 49142	cytopenias
T1175	adversereaction 49144 49152	bleeding
T1177	adversereaction 49154 49167	easy bruising
T1179	adversereaction 49169 49178	petechiae
T1181	adversereaction 49182 49189	purpura
T1183	adversereaction 49191 49197	pallor
T1185	adversereaction 49199 49207	weakness
T1187	adversereaction 49211 49219	fatigue)
T1189	adversereaction 49451 49455	rash
T1191	adversereaction 49457 49463	bullae
T1193	adversereaction 49468 49507	desquamation of the skin or oral mucosa
T1195	adversereaction 49581 49590	infection
T1197	adversereaction 49597 49605	pyrexia)
T1199	tradename 49728 49735	Zevalin
T1201	tradename 49892 49899	Zevalin
T1203	tradename 50057 50064	Zevalin
T1205	tradename 50116 50123	Zevalin
T1207	nanoparticle 50128 50149	ibritumomab tiuxetan)
T1209	company 50170 50194	Spectrum Pharmaceuticals
T1211	company 50196 50200	Inc.
T1213	tradename 50263 50270	Zevalin
T1215	company 50303 50327	Spectrum Pharmaceuticals
T1217	company 50329 50333	Inc.
T1219	u.s.patent 50386 50387	5
T1221	u.s.patent 50388 50391	736
T1223	u.s.patent 50392 50395	137
T1225	u.s.patent 50397 50398	5
T1227	u.s.patent 50399 50402	776
T1229	u.s.patent 50403 50406	456
T1231	u.s.patent 50408 50409	5
T1233	u.s.patent 50410 50413	843
T1235	u.s.patent 50414 50417	439
T1237	u.s.patent 50419 50420	6
T1239	u.s.patent 50421 50424	207
T1241	u.s.patent 50425 50428	858
T1243	u.s.patent 50430 50431	6
T1245	u.s.patent 50432 50435	399
T1247	u.s.patent 50436 50439	061
T1249	u.s.patent 50441 50442	6
T1251	u.s.patent 50443 50446	682
T1253	u.s.patent 50447 50450	734
T1255	u.s.patent 50452 50453	6
T1257	u.s.patent 50454 50457	994
T1259	u.s.patent 50458 50461	840
T1261	u.s.patent 50463 50464	7
T1263	u.s.patent 50465 50468	229
T1265	u.s.patent 50469 50472	620
T1267	u.s.patent 50474 50475	7
T1269	u.s.patent 50476 50479	381
T1271	u.s.patent 50480 50483	560
T1273	u.s.patent 50485 50486	7
T1275	u.s.patent 50487 50490	422
T1277	u.s.patent 50491 50494	739
